XML 18 R7.htm IDEA: XBRL DOCUMENT v3.25.3
REVENUE
 9 Months Ended
Sep. 30, 2025
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
The following table summarizes the disaggregation of revenue by nature:
Three Months Ended September 30,Nine Months Ended September 30,
Dollars in millions2025202420252024
Net product sales$11,850 $11,483 $34,645 $34,967 
Alliance revenues125 105 332 355 
Other revenues
247 304 715 636 
Total Revenues$12,222 $11,892 $35,692 $35,958 

The following table summarizes GTN adjustments:
Three Months Ended September 30,Nine Months Ended September 30,
Dollars in millions2025202420252024
Gross product sales$22,494 $21,223 $64,548 $61,298 
GTN adjustments(a)
Charge-backs and cash discounts(3,475)(2,967)(9,840)(8,366)
Medicaid and Medicare rebates(4,887)(4,577)(13,244)(11,525)
Other rebates, returns, discounts and adjustments(2,281)(2,196)(6,819)(6,440)
Total GTN adjustments(b)
(10,644)(9,740)(29,903)(26,331)
Net product sales$11,850 $11,483 $34,645 $34,967 
(a) Includes reductions/(increases) to GTN adjustments for product sales made in prior periods resulting from changes in estimates of $87 million and $418 million for the three and nine months ended September 30, 2025 and $42 million and $103 million for the three and nine months ended September 30, 2024, respectively.
(b) Includes U.S. GTN adjustments of $9.8 billion and $27.5 billion for the three and nine months ended September 30, 2025 and $8.9 billion and $23.9 billion for the three and nine months ended September 30, 2024, respectively.
The following table summarizes the disaggregation of revenue by product and region:
Three Months Ended September 30,Nine Months Ended September 30,
Dollars in millions2025202420252024
Growth Portfolio
Opdivo$2,532 $2,360 $7,356 $6,825 
Opdivo Qvantig
67 — 105 — 
Orencia964 936 2,697 2,682 
Yervoy739 642 2,090 1,855 
Reblozyl615 447 1,661 1,226 
Opdualag299 233 835 674 
Breyanzi359 224 966 484 
Camzyos
296 156 714 379 
Zeposia161 147 418 408 
Abecma
137 124 326 301 
Sotyktu80 66 206 163 
Krazati
53 34 149 87 
Cobenfy
43 — 105 — 
Other Growth products(a)
514 443 1,388 1,116 
Total Growth Portfolio
6,857 5,812 19,016 16,200 
Legacy Portfolio
Eliquis3,746 3,002 10,991 10,138 
Revlimid575 1,412 2,349 4,434 
Pomalyst/Imnovid675 898 2,041 2,722 
Sprycel119 290 413 1,088 
Abraxane74 253 284 701 
Other Legacy products(b)
177 225 599 675 
Total Legacy Portfolio
5,365 6,080 16,676 19,758 
Total Revenues$12,222 $11,892 $35,692 $35,958 
United States$8,329 $8,232 $24,721 $25,509 
International(c)
3,602 3,389 10,193 9,803 
Other(d)
290 271 778 646 
Total Revenues$12,222 $11,892 $35,692 $35,958 
(a)    Includes Augtyro, Onureg, Inrebic, Nulojix, Empliciti and royalty revenues.
(b)    Includes other mature brands.
(c)     Includes Puerto Rico.
(d)    Other revenues include royalties and alliance-related revenues for products not sold by BMS's regional commercial organizations.

Revenue recognized from performance obligations satisfied in prior periods was $318 million and $992 million for the three and nine months ended September 30, 2025 and $238 million and $496 million for the three and nine months ended September 30, 2024, respectively, consisting primarily of royalties for out-licensing arrangements and revised estimates for GTN adjustments related to prior period sales.